drugset / Trial / NCT02159365
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
NaSingle-groupOpen-labelTreatment
Summary
To explore whether Elotuzumab dose administration over approximately 60 minutes is feasible and safe.
Timeline
- Start
- 2014-03-08
- Primary completion
- 2016-06-30
- Completion
- 2018-07-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elotuzumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Background | Dexamethasone | Small molecule | 40 mg | Oral |
| Background | Lenalidomide | Other / unclassified | 25 mg | Oral |